In "Episode 6" of the series on "Present and future of diagnostics in prostate cancer", Assoc. Prof. Pawel Rajwa (PL) speaks with Prof. Peter Carroll (US) about the shifting landscape of active surveillance for intermediate-risk prostate cancer.

Traditionally reserved for low-risk cases, active surveillance is now being considered for select patients with grade group 2 disease - especially when diagnosed through advanced techniques like MRI-targeted biopsy.

Prof. Carroll explains how MRI has changed both the decision-making process and the biopsy approach, helping identify candidates with low risk of progression. The conversation addresses the potential to reduce overtreatment, minimise invasive follow-ups, and improve quality of life without compromising outcomes. Together, they examine how emerging data and imaging innovations are informing a more nuanced, patient-specific approach to prostate cancer care.

For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.